This page shows the latest Mundipharma news and features for those working in and with pharma, biotech and healthcare.
Mundipharma has strengthened its partnership with biopharmaceutical group Celltrion Healthcare by securing rights to its trastuzumab biosimilar. ... As per terms of the deal, Mundipharma - a global network of privately owned independent companies - has
Novartis’unit Sandoz and Celltrion/Mundipharma’s Truxima have also claimed a European approval for its biosimilar versions of Roche’s immunotherapy drug MabThera (rituximab).
Also given the nod were two drugs from Mundipharma intended to help people with opioid addiction – Nyxoid (naloxone) and Zubsolv (buprenorphine/naloxone), while Spanish drugmaker Grifols got the go-ahead for
It was the second biosimilar of Roche's drug to be approved in Europe after Celltrion/Mundipharma's Truxima, which also pipped Sandoz to the filing post in the US after
The recent problems of the generics sector have lessons for research-based companies too
competition from Pfizer's Inflectra, Mundipharma's Remsima and Samsung Bioepis' Renflexis/Flixabi.
More from news
Approximately 9 fully matching, plus 51 partially matching documents found.
Finally it is always encouraging to see medium size companies like Mundipharma and Jazz finding and licensing new product opportunities. ... Mundipharma built its oncology franchise following the acquisition of an old anti-cancer drug and the deal to
When science is not enough. Mundipharma’s Will Dunlop on a new framework to guide development programmes to a better destination. ... programme, ”says Will Dunlop, head of market access for Mundipharma International, who has been developing the
For example in Europe both Pfizer (Hospira) in 2009 and Mundipharma in 2014 have rights to Celltrion's infliximab.
This first infliximab biosimilar was developed and manufactured by Celltrion and is marketed by various partners, notably Hospira under the brand name Inflectra and Mundipharma as Remsima.
Divestment of US rights. 1, 050. Esteve/ Mundipharma. Discovery and development of next generation pain products including E-52862 in P2 for neuropathic pain.
More from intelligence
Approximately 2 fully matching, plus 7 partially matching documents found.
His new role will see him take responsibility for strengthening Mundipharma ’s network in Europe and focus on its alliances. ... Prior to his time at Mundipharma, he served Napp Pharmaceuticals and Janssen in various capacities.
Mundipharma appoints chief information officer. Philippe Mazas joins the UK-based pharma network from Smith &Nephew. ... His new role will see him take responsibility for the IT services provided to Mundipharma ’s global network of associated companies.
Hywel Day joins Napp Pharmaceuticals. Moves from Mundipharma to take up managing director role. ... It’s a return to Napp for Day, who spent 10 years at Napp from 2003, before moving to Mundipharma.
Napp names new managing director. Alberto Martinez joins from Mundipharma. UK-based Napp Pharmaceuticals has appointed Alberto Martinez as the company's new managing director. ... Martinez's previous experience includes time as marketing manager at
Clients include Boehringer Ingelheim, Mundipharma and Novartis.
More from appointments
Approximately 2 fully matching, plus 5 partially matching documents found.
Commissioned by Mundipharma, the paper is titled ‘ Patient and oncologist perceptions regarding symptoms and impact on quality-of-life of oral mucositis in cancer treatment: results from the Awareness Drives Oral
2015, See potential in a different angle, Levact (Mundipharma). 44 7595 003744.
GlaxoSmithKlein. Meningitis Trust. Mundipharma. Napp Pharmaceuticals. Novartis. Pfizer. Roche. Sanofi. Shire.
GlaxoSmithKlein. Meningitis Trust. Mundipharma. Napp Pharmaceuticals. Novartis. Pfizer. Roche. Sanofi. Shire.
at global and local affiliate level for clients such as Merck Serono, Lundbeck, Pfizer and MundiPharma.
More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.
Accession was a born from a passion and a vision. A passion to harness the power of market access to...